Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ
Ehave Announces Mycotopia Therapies Reaches Definitive Agreement on Triangular Merger with Ei.Ventures to Form PSLY.com to List on NASDAQ
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies valued at more than $24 million, as of Friday's closing price; Plans partial distribution to shareholders
截至周五收盘价，Ehave拥有约9,793,754股Mycotopia Therapia股票，价值超过2400万美元；计划向股东部分分配
MIAMI, May 23, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, announced today that its Mycotopia Therapies (OTC: TPIA) subsidiary has signed a definitive agreement to complete a triangular merger with Ei.Ventures, an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology, to form PSLY.COM. The companies anticipate closing the transaction on or about July 30, 2022.
迈阿密，2022年5月23日（GLOBE NEWSWIRE）——领先的医疗保健服务和科技公司Ehave, Inc.（OTC Pink：EHVVF）（以下简称 “公司”）今天宣布，其Mycotopia Therapies（场外交易代码：TPIA）子公司已签署最终协议，完成与通过精神活性化合物、营养品增强心理健康的早期科技公司Ei.Ventures的三角合并还有技术，组成了 PSLY.COM。两家公司预计将在2022年7月30日左右完成交易。
Ehave owns approximately 9,793,754 shares of Mycotopia Therapies, which was valued around $28.4 million at the close of business Friday. As of May 16, 2022 Ehave currently has 276,775,899 shares outstanding, which values Ehave's stake in Mycotopia Therapies at more than $0.10 per share. In addition to Ehave's Mycotopia Therapies stake, the company owns its KetaDASH subsidiary, MetaHealthU, and is developing partnerships with SelfDecode, COGAPPS, GoMeyra, and Vastmindz.
Ehave拥有Mycotopia Therapia Therapis的约9,793,754股股份，截至周五收盘时，该股的价值约为2,840万美元。截至2022年5月16日，Ehave目前有276,775,899股已发行股份，估值Ehave在Mycotopia Therapis的股份超过每股0.10美元。除了Ehave的Mycotopia Therapis股份外，该公司还拥有其KetaDash子公司MetaHealthU，并正在与SelfDecode、COGAPPS、GoMeyra和Vastmindz建立合作伙伴关系。
The transaction between Mycotopia Therapies and Ei.Ventures will be structured as a triangular merger. The two companies will form a new holding company, PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing. Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. The company has been performing most of its research in Jamaica, where psilocybin is legal, as well as working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine. Ei.Ventures' ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. By leveraging blockchain, emerging technologies and the Metaverse, Ei.Ventures intends to create a safe, efficient, and secure way to provide telehealth services in general, as well as for psychoactive therapeutics.
Mycotopia Therapia Therapis和Ei.Ventures之间的交易将结构为三角合并。两家公司将组建新的控股公司PSLY.COM，并在合并后作为子公司运营。PSLY.COM将申请在纳斯达克上市。Mycotopia Therapias 的主要重点是蘑菇和迷幻的机会。该公司的大部分研究都在牙买加进行，那里的迷幻药是合法的，并与荷兰最大的大麻实验室之一合作开发迷幻药，以共同许可某些分子用于迷幻药物。Ei.Ventures的目标是提供政府批准的治疗方案，以应对当前的全球心理健康疫情。通过利用区块链、新兴技术和元宇宙，Ei.Ventures打算创造一种安全、高效和可靠的方式来提供一般的远程医疗服务以及精神活性疗法。
Ben Kaplan, CEO of Ehave, Inc., said, "The statistics on the declining state of mental health in America are devastating. Globally, the statistics are even more bleak. Ei.Ventures recently completed a successful Reg A offering, which raised over $25 million. Their plan is not only to profit from delivering governmental approved therapeutic treatment options that address the current global mental healthcare crisis, but to provide solutions for the millions of people who want to improve their mental health. Not only will this transaction afford Ei.Ventures with better opportunities to raise capital in order to execute its business plan, it is a fantastic opportunity to monetize Ehave's Mycotopia Therapies asset for our shareholders."
Ehave, Inc. 首席执行官本·卡普兰说：“关于美国心理健康状况下降的统计数据是毁灭性的。在全球范围内，统计数据更加惨淡。Ei.Ventures最近成功完成了Reg A发行，筹集了超过2500万美元的资金。他们的计划不仅是通过提供政府批准的应对当前全球心理健康危机的治疗方案中获利，而且还要为数百万想要改善心理健康的人提供解决方案。这笔交易不仅将为Ei.Ventures提供更好的筹集资金以执行其商业计划的机会，而且也是为我们的股东通过Ehave的Mycotopia Therapia Therapia资产获利的绝佳机会。”
In America, 52.9 million people, or 21% of U.S. adults, experienced mental illness in 2020, 14.2 million people, or 5.6% of U.S. adults, experienced serious mental illness in 2020. Even more alarming is that 16.5% of U.S. youth aged 6-17 experienced a mental health disorder in 2016, 6.7% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2020, and suicide has emerged as the 2nd leading cause of death among people aged 10-34.
在美国，2020年有5,290万人（占美国成年人的21％）患有精神疾病，2020年有1,420万人（占美国成年人的5.6％）患有严重的精神疾病。更令人震惊的是，2016年有16.5％的6-17岁美国年轻人患有精神疾病，2020年有6.7％的美国成年人同时患有药物滥用障碍和精神疾病，自杀已成为10-34岁人群的第二大死因。
Ehave CEO Ben Kaplan continued, "As far as our Ehave shareholders are concerned, this business combination represents the culmination of monetizing our Mycotopia Therapies asset. At the end of December 2020, we announced we would reposition Mycotopia Therapies asset by merging it with 20/20 Global. We closed the transaction in January 2021, and applied to FINRA to change the name of the company from 20/20 Global to Mycotopia Therapies. Approximately one-year later, I announced plans to merge with Ei.Ventures and create PSLY.com in this transaction valued at more than $380 million. In addition to receiving shares of PSLY.com, our Ehave shareholders still own our growing KetaDASH subsidiary, MetaHealthU, and our developing partnerships with incredible companies like SelfDecode, COGAPPS, GoMeyra, and Vastmindz."
Ehave首席执行官本·卡普兰继续说：“就我们的Ehave股东而言，这种业务合并代表了通过我们的Mycotopia Therapia资产获利的高潮。2020年12月底，我们宣布将重新定位Mycotopia Therapias 资产，将其与20/20 Global合并。我们于2021年1月完成了交易，并向美国金融监管局申请将公司名称从20/20 Global更改为Mycotopia Therapies。大约一年后，我宣布计划与Ei.Ventures合并，在这笔价值超过3.8亿美元的交易中创建PSLY.com。除了获得PSLY.com的股份外，我们的Ehave股东仍然拥有我们不断增长的KetaDash子公司MetaHealthU，以及我们与SelfDecode、COGAPPS、Gomeyra和Vastmindz等令人难以置信的公司不断发展的合作伙伴关系。”
Ehave will issue an additional press release, as well as file the required documents with the SEC, discussing distribution of Mycotopia Therapies/PSLY.COM shares to shareholders, as well as a timeline.
Ehave将发布另一份新闻稿，并向美国证券交易委员会提交所需文件，讨论向股东分配Mycotopia Therapies/psly.com股票以及时间表。
About Ehave, Inc.
关于 Ehave, Inc.
Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: .
Ehave是一家领先的医疗保健服务和技术公司，致力于通过设计用于治疗大脑健康的新化合物和新的治疗方案，将迷幻药转化为治疗药物。与我们的科学家和心理健康专业人员网络一起，我们的使命是为患者创造安全有效的治疗方法，以解决多种心理健康问题，利用临床数据来帮助我们实现最佳的患者疗效。Ehave的业务遍及整个美国、加拿大、牙买加和澳大利亚。有关Ehave的更多信息，请访问公司的网站：:.
About Mycotopia Therapies
关于真菌托邦疗法
Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company's website at:
Mycotopia Therapies 专注于帮助您治愈和恢复生活。您的康复之旅是了解病因，并通过迷幻增强的心理治疗，与专业的心理健康从业人员团队和尖端技术相结合，致力于心理健康。迷幻疗法是一种提供治疗的整体和精神方法，多年来一直显示出成功的治疗方法。有关 Mycotopia Therapies 的更多信息可在公司网站上找到，网址为：
About Ei.Ventures Inc.:
Ei.Ventures Inc. is an early-stage tech company empowering mental wellness through psychoactive compounds, nutraceuticals and technology. Ei is leveraging blockchain, emerging technologies and the Metaverse to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. It is the goal of Ei to utilize the development of these technologies, to create a safe, efficient, and secure way to provide telehealth services in general and specifically to the psychoactive therapeutics. Additional information on Ei can be found on the Ei's website at:
关于 Ei.Ventures Inc.：
Ei.Ventures Inc. 是一家早期科技公司，通过精神活性化合物、营养品和技术来增强心理健康。Ei正在利用区块链、新兴技术和元宇宙来提供政府批准的治疗方案，以应对当前的全球心理健康疫情。Ei的目标是利用这些技术的发展，创造一种安全、高效和可靠的方式来提供一般的远程医疗服务，特别是向精神活性疗法患者提供远程医疗服务。有关Ei的更多信息，请访问Ei的网站，网址为：
Forward-Looking Statement Disclaimer
前瞻性声明免责声明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,
本新闻稿包含1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类陈述前面可能有 “打算”、“可能”、“将”、“计划”、“预期”、“预期”、“项目”、“预测”、“估计”、“目标”、“相信”、“希望”、“潜力” 或类似词语。前瞻性陈述基于某些假设，受各种已知和未知风险和不确定性的影响，其中许多风险和不确定性超出了公司的控制范围，无法预测或量化，因此，实际结果可能与此类前瞻性陈述所表达或暗示的结果存在重大差异：（i）公司研究、制造和其他开发工作的启动、时机、进展和结果；（ii）公司推进其产品以成功完成开发和商业化的能力化;(iii) 公司产品的制造、开发、商业化和市场接受度；(iv) 缺乏足够的资金为产品开发和业务运营提供资金；(v) 公司行业内具有竞争力的公司和技术以及竞争产品的推出；(vi) 公司建立和维持公司合作的能力；(vii) 关键管理人员的流失；(viii) 公司能够建立和维持的保护范围涵盖其产品的知识产权，以及其在不侵犯他人知识产权的情况下开展业务的能力；(ix) 可能未能遵守适用的健康信息隐私和安全法律以及其他州和联邦隐私和安全法；以及 (x) 难以预测美国食品和药物管理局及其法规的行动。本新闻稿中包含的所有前瞻性陈述仅在本新闻稿发布之日作出。除非法律要求，否则公司没有义务更新任何书面或口头的前瞻性陈述。有关公司以及可能影响前瞻性陈述实现的风险因素的更多详细信息包含在Ehave, Inc.的 “风险因素” 标题下。于2015年9月24日向美国证券交易委员会（SEC）提交的经修订的F-1表格注册声明，该声明可在美国证券交易委员会的网站上查阅，
For Media and Investor Relations, please contact:
有关媒体和投资者关系事宜，请联系：
David L. Kugelman
大卫·L·库格尔曼
(866) 692-6847 Toll Free - U.S. & Canada
(866) 692-6847 免费电话——美国和加拿大
(404) 281-8556 Mobile and WhatsApp
(404) 281-8556 手机和 WhatsApp
Email: Ir@Ehave.com
电子邮件：Ir@Ehave.com
Skype: kugsusa
Skype：kugsusa
译文内容由第三方软件翻译。